



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/85, C07K 14/505, C12N 5/16	A1	(11) International Publication Number: WO 00/14261 (43) International Publication Date: 16 March 2000 (16.03.00)
(21) International Application Number: PCT/EP99/06465 (22) International Filing Date: 2 September 1999 (02.09.99) (30) Priority Data: 98116821.4 4 September 1998 (04.09.98) EP (71) Applicant (for all designated States except US): CYTOS BIOTECHNOLOGY AG [CH/CH]; Wagistrasse 21, CH-8952 Zürich-Schlieren (CH). (72) Inventor; and (75) Inventor/Applicant (for US only): RENNEN, Wolfgang, Andreas [CH/CH]; Weinbergstrasse 64, CH-8006 Zürich (CH). (74) Agent: MAIWALD, Walter; Maiwald Patentanwalts-GmbH, Elisenstrasse 3, D-80335 München (DE).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PRODUCTION OF HUMAN ERYTHROPOIETIN (57) Abstract <p>The present invention relates to the production of the recombinant human erythropoietin in mammalian cells, particularly in kidney cells, transformed with an expression vector containing the human erythropoietin gene driven by the myeloproliferative sarcoma virus promoter. Further, this invention relates to the preparation of erythropoietin-producing cells using the tryptophan synthetase gene from <i>E. coli</i> as a selectable marker. The invention is also directed to an improved cell culture process using a serum-free and protein-free culture medium.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

Production of human erythropoietin

10 The present invention relates to the production of recombinant human erythropoietin in mammalian cells, particularly in kidney cells, transformed with an expression vector containing the human erythropoietin gene driven by the myeloproliferative sarcoma virus promoter. Further, this invention relates to the preparation of erythropoietin-producing cells using the tryptophan synthetase gene from *E. coli* as a selectable marker. The invention is also directed to an improved cell culture process
15 using a serum-free and protein-free culture medium.

Erythropoietin is the principal hormone in the regulation and maintenance of a physiological level of circulating erythropoietin mass, it stimulates cellular differentiation of bone-marrow stem cells at an early stage of erythropoiesis and
20 accelerates the proliferation and maturation of terminally differentiating cells into erythrocytes. Erythropoietin is a glycoprotein with a molecular weight ranging from 34 to 38 kDa of which approximately 40 to 50 % account for carbohydrate moieties. It is produced primarily in the kidneys of adult and the liver of fetal mammals. When the body is in a healthy state wherein tissues receive sufficient oxygenation from the
25 existing number of erythrocytes, erythropoietin is present in the plasma in very low concentrations. This normal low concentration is enough to stimulate replacement of red blood cells which are lost normally through aging. Under conditions of hypoxia when oxygen transport by blood cells in the circulation is reduced, the amount of erythropoietin in the circulation is increased. Hypoxia may be caused by loss of large
30 amounts of blood through hemorrhage, destruction of red blood cells by over-exposure to radiation, reduction in oxygen intake due to high altitudes or prolonged unconsciousness, or various forms of anemia. In the healthy organism, a homeostatic mechanism induces the increase of the erythropoietin concentration in the blood depending upon the degree of the anemia to maintain an optimal hematocrit.

35

- 2 -

5 However, in the case of anemia caused by chronic renal deficiency, erythropoietin can not be produced due to the progressive destruction of kidney mass and kidney function and hence the erythropoietin concentrations in the circulation do not increase.

10 Erythropoietin is now established as the accepted treatment of various forms of anemia, particularly in chronic renal failure. Further clinical applications of pharmaceutical products containing erythropoietin are the prevention of anemia of patients who receive hemodialysis because of renal insufficiency or after nephrectomy and the promotion of recovery of postoperative patients by stimulating the formation
15 of erythrocytes.

 Recombinant human erythropoietin has become available for the treatment of anemia as the first recombinant biomedicine produced in mammalian cells. For example, in Germany, recombinant erythropoietin, produced in a CHO-K1 cell line, is sold by
20 Janssen-Cilag under the trade Erypo®.

 The human erythropoietin gene has been isolated and characterized already in 1985 (Lin *et al.* (1985) Proc. Natl. Acad. Sci. USA 82, 7580-7584; Jacobs *et al.* (1985) Nature 313, 806-810). The entire coding region of this gene is contained in a 5.4-
25 kilobase *Hind*III-*Bam*HI fragment, the gene containing four introns (1562 base pairs) and five exons (582 base pairs), which encode a 27-amino acid signal peptide for secretion of human erythropoietin and a 166-amino acid mature protein. Further, erythropoietin contains sialic acid, which is required for in vivo activity. Although unglycosylated erythropoietin has in vitro activity, it shows no activity in vivo. This
30 is due to the extremely low half life of the unglycosylated protein in human circulation.

5 Consequently, erythropoietin for therapeutic use has to be manufactured in mammalian cells resulting in similar glycosylation as the native human glycoprotein.

Lin *et al.*, supra, describes the production of recombinant human erythropoietin in CHO (Chinese hamster ovary) cells, stably transformed with an expression vector
10 containing the genomic erythropoietin gene driven by the SV40 late promoter, while Jacobs *et al.*, supra, discloses the production of erythropoietin in transient expression experiments in COS cells (a cell line derived from monkey cells that contains an integrated segment of SV40 DNA) cells, transfected with a vector containing the human erythropoietin cDNA under control of the adenovirus major late promoter.

15 Furthermore, European Patent Application No. 0 148 605 describes the isolation and characterization of a monkey erythropoietin cDNA clone and a human genomic clone, and the production of recombinant erythropoietin in COS-1 and CHO cell lines, wherein monkey and human erythropoietin gene expression is under control of
20 the SV40 late promoter.

European Patent Application No. 0 225 231 describes a process for producing erythropoietin in stably transfected mammalian cell lines, wherein an erythropoietin gene is expressed under control of either the adenovirus-2 major late promoter, or the
25 MT-I (metallothionein-I) promoter of mouse.

Further, European Patent Application No. 0 232 034 describes the production of recombinant erythropoietin in human cells, namely in Namalwa cells, using the SV40 promoter to drive expression of erythropoietin and using the neomycin
30 resistance (neo^r) gene as the selectable marker.

Similarly, European Patent Application No. 0 236 059 discloses the production of erythropoietin in kidney cells, transfected with an expression vector carrying the

5 human erythropoietin gene under control of the M-MuLV (Moloney murine leukemia virus) LTR promoter, and the *neo^r* gene as the selectable marker.

However, there is still a need in the art for efficient expression systems suitable in large scale production of erythropoietin.

10

It is thus an object of the present invention to provide an erythropoietin expression vector and a process for the production of recombinant erythropoietin based on said expression vector which provides high level erythropoietin expression in mammalian cells.

15

Surprisingly, it has been found that using a novel host vector system which is based on the MPSV (myeloproliferative sarcoma virus) promoter and a genomic erythropoietin DNA sequence, the erythropoietin product in mammalian cells represents a very large fraction of up to above 50 % of the total protein in the cell culture supernatant.

20

According to the present invention, there is, thus, provided a novel expression vector, wherein the human erythropoietin gene is operably linked to the MPSV (myeloproliferative sarcoma virus) promoter. Further, there is provided a process for production of erythropoietin in a mammalian host cell comprising the step of culturing under suitable nutrient conditions a mammalian host cell transfected with the novel expression vector.

25

The myeloproliferative sarcoma virus has been previously described by Ostertag *et al.* (1980) J. Virol. 33, 573-582; it is known to transform murine fibroblasts and to cause also changes in cells of the hemopoietic system. The MPSV promoter, used within this invention, has already been studied by, e.g., Artelt *et al.* (1988) Gene 68, 213-219.

30

5

In a preferred embodiment, the process for production of erythropoietin in a mammalian host cell comprises the steps of (1) preparation of an erythropoietin expression vector in which erythropoietin expression is under control of the MPSV promoter, (2) introducing said erythropoietin expression vector into a mammalian host cell, (3) culturing said cell to produce erythropoietin and (4) recovering the erythropoietin from the cell culture medium.

10

Preferably, the mammalian host cell is a kidney cell, most preferred a baby hamster kidney (BHK) cell, such as BHK 21.

15

Most of the prior art uses the DHFR selection system, which relies on the fact that the enzyme dihydrofolate reductase (DHFR), coded for by the DHFR gene, can be inhibited by the drug methotrexate, and that cells propagated in media lacking hypoxanthine and thymidine are inhibited or killed by methotrexate. Under appropriate conditions, e.g. minimal concentrations of methotrexate, cells resistant to and able to grow in methotrexate-containing medium, can be obtained. These cells are found to be resistant to methotrexate due to an amplification of the number of their DHFR genes, resulting in increased production of DHFR enzyme. The surviving cells can, in turn, be treated with increasing concentrations of methotrexate, resulting in cell strains containing greater numbers of DHFR genes. The gene of interest, e.g. an erythropoietin gene, carried on the expression vector along with the DHFR gene or transformed with the DHFR gene is frequently found also to be increased in their gene copy number. Thus, the DHFR system is generally used in a combined selection/amplification approach. However, several problems are connected to the use of the DHFR selection amplification system. Due to the high toxicity of methotrexate the selection pressure cannot be maintained throughout the manufacturing process. High producers often revert to a mediocre productivity once methotrexate is removed from the culture medium.

30

5

Further, the neo marker, another antimetabolite resistance marker frequently used in the prior art, has the principal disadvantage that relatively large amounts of the expensive drug G418 are needed for the selection of transformants in mammalian cells.

10

Thus, it is a further object of the invention to provide a process for the large scale production of erythropoietin in mammalian cells which overcomes the disadvantages of selectable marker systems previously described in the prior art of erythropoietin production, and which avoids toxic additives.

15

According to the present invention, there is provided a process for the production of erythropoietin in mammalian host cells, which are selected on the basis of their ability to produce tryptophan.

20

Most mammalian cells lack the enzymatic pathways required for synthesis of certain, so-called essential amino acids and thus must acquire them from exogenous sources. The absence of even one essential amino acid causes approximately 50 % inhibition of protein synthesis; a basal rate is apparently sustained by turnover of endogenous proteins. In 1988, Hartman and Mulligan (Proc. Natl. Acad. Sci. USA 85, 8047-8051) discovered that tryptophan can be applied as a metabolic marker for selection of transformant mammalian cells. The marker system is based on the tryptophan synthetase gene (*trpB*) of *E.coli*, which catalyses conversion of indole to tryptophan. However, so far, the *trpB* gene has never been described as a useful selectable marker in the production of erythropoietin.

25

30

Surprisingly, it has been found that by use of *trpB* as the selectable marker high expression levels of erythropoietin can be observed in selected host cells in the absence of gene amplification.

5

In a preferred embodiment, the tryptophan synthetase gene is cotransfected with the erythropoietin expression vector to a host cell. However, it is, of course, also possible to transfect the mammalian host cell with a single nucleic acid molecule which contains the DNA sequence coding for human erythropoietin under control of an appropriate promoter, preferably the MPSV promoter, and the *trpB* gene also under control of an appropriate promoter.

15

Due to the fact that serum, e.g. fetal bovine serum, which is usually added to the cell culture medium, shows a background of tryptophan, the serum has to be dialyzed to remove tryptophan. Therefore, the *trpB* selection system is especially useful in large scale production in serum-free medium, wherein tryptophan can be substituted with indole, which is neither toxic nor expensive, more easily.

20

Therefore, in a preferred embodiment, the process for the production of large amounts of erythropoietin comprises the step of culturing mammalian host cells in a serum-free medium, which lacks exogenous tryptophan. Preferably, the host cell is a kidney cell, preferably a BHK cell, such as BHK 21.

25

30

As mentioned above, current manufacturing processes are based on roller bottle cultivation of recombinant mammalian cells, e.g. recombinant Chinese Hamster Ovary cells, which grow in a medium that contains fetal bovine serum. The addition of serum is mandatory to provide the necessary growth factors for cellular proliferation. The presence of this additive, however, is detrimental in several aspects: the major concern relates to product safety. The risk of transferring pathogenic agents from the manufacturing process via the pharmaceutical product to the patient has gained significant consideration, in particular, since the widespread occurrence of bovine spongiform encephalopathy (BSE). Prions, as well as viruses that are not inactivated during downstream processing impose a significant risk at the

5 process. As a consequence of this concern, safety measures necessary for minimising this risk are tremendous, ranging from extensive testing of raw materials (serum) to final product characterization.

10 In view of the fact that avoidance of any biologically derived material in the manufacturing process not only significantly increases product quality and safety, but at the same time reduces manufacturing costs and simplifies product approval, there is a considerable interest in serum-free and protein-free culture media for the culturing of recombinant mammalian cells.

15 For example, EP-A-0 148 605 discloses a method for production of erythropoietin from CHO cells in serum-free growth media, being high glucose DMEM supplemented with 0.1 mM non-essential amino acids and L-glutamine, or a 50-50 mixture of high glucose DMEM and Ham's F12 supplemented with 0.05 mM non-essential amino acids and L-glutamine.

20 Further, European Patent Application No. 0 513 738 describes the cultivation of mammalian cells in a serum-free medium, which contains recombinant insulin from procaryotic cells instead of animal insulin and transferrin, and a water-soluble ferric compound.

25 EP-A-0 531 911 describes a process for cultivating vero cells in a protein-free medium, wherein culture surfaces from polyvinylformal and polyvinylbutyral are used, and wherein the cells are preferably cultivated as a continuous monolayer.

30 However, in most cases, cultivation in serum-free medium is mentioned only in connection with cell lines which were previously adapted for growth in serum-free media by special adaptive strategies, e.g. the adapted cell line CHO SSF3, described by Zang *et al.* (1995) in *Bio/Technology* 13, 389-392), or the CHO DUKX cell

5 lineage described by Sinacore *et al.* (1996) in Biotechnology and Bioengineering 52, 518-528.

It has been found that BHK 21 cells grow without adaptation or genetic engineering in the serum- and protein-free medium formulations Turbodoma and Turbodoma HP-
10 1 of the manufacturer Dr. F. Messi Cell Culture Technologies, Buhrain 14, 8052 Zurich, Switzerland. After transfer of the cells from Eagle's minimum essential medium containing 10 % fetal calf serum and 2 mM L-Glutamin into the Turbodoma medium, cellular proliferation continued without significant decline in viability or growth rate. Moreover this medium formulation allows cultivation of BHK 21 cells
15 alternatively in suspension or attached to carriers. Accordingly, a broad spectrum of reactor systems and process parameters can be applied.

In a preferred embodiment of the invention, the mammalian cell line, which is cultured in the serum-free and protein-free medium of the invention, and which is
20 preferably the BHK 21 cell line, is capable of producing human erythropoietin. Most preferably, the serum-free and protein-free medium contain indole, however no tryptophan, so that only such cells are able to grow which are capable of producing tryptophan due to their tryptophan synthetase activity. This tryptophan synthetase enzymatic activity is accomplished by transfecting the cells with a nucleic acid
25 molecule carrying the *trpB* gene from *E. coli*. The *trpB* gene can be under control of any suitable promoter, i.e. a promoter that promotes transcription in a mammalian cell, e.g. viral promoters such as the simian virus 40 (SV40) early promoter, the HIV and the MPSV promoter.

30 Therefore, in a preferred embodiment, the invention is directed to a process of producing human erythropoietin, which comprises the steps of (1) preparing an erythropoietin expression vector in which erythropoietin expression is under the control of the MPSV promoter, (2) introducing said erythropoietin expression vector

5 into BHK 21 cells, (3) culturing said cells in a protein-free and serum-free medium, comprising indole, however lacking exogenous tryptophan.

By using an erythropoietin expression vector in which erythropoietin expression is under control of the MPSV promoter and culturing eucaryotic host cells transformed
10 with this expression vector in a protein-free and serum-free medium, we found much higher EPO expression levels than using promoter/erythropoietin fusion constructs described in the prior art. The same applies to the production of erythropoietin in eucaryotic cells transformed with the MPSV/erythropoietin fusion construct in protein-free and serum-free medium in comparison to conventional medium or in
15 comparison to cell lines which have previously been adapted for growth in serum-free media as described in the prior art.

Within this specification, the term "erythropoietin" is meant to define a protein which has the biological activity of erythropoietin, i.e. it is able to stimulate
20 erythropoiesis. The protein may be coded by a genomic DNA sequence or by a cDNA clone. Further, the term "erythropoietin" also comprises a protein fragment, which has the biological activity of naturally-occurring erythropoietin. Preferably, the recombinant protein corresponds fully, or at least substantially, to naturally-occurring human erythropoietin with respect to amino acid sequence and number (166 amino
25 acids in the mature protein), a molecular weight of between approximately 34 to 38 kDa, of which a proportion of about 40% to 50% accounts for carbohydrate moieties.

The gene for human erythropoietin is available, e.g., from the American Type Culture Collection under ATCC No. 40381, as a lambda HE 1 phage lysophilisate.

30 Further, the term "promoter" is meant to define a DNA sequence that precedes a gene (genomic or cDNA clone) in a nucleic acid molecule and provides a site for initiation of the transcription of the gene into mRNA. Accordingly, the term "expression

- 11 -

5 vector" defines a nucleic acid molecule, in which a promoter is operably linked to a gene to be expressed, and which enables a host cell to produce the protein encoded by the gene after the vector has been introduced into the host cell. However, in addition to the gene of interest (particularly, an erythropoietin gene), operably fused to a promoter (particularly, the MPSV promoter), the expression vector may contain
10 further promoter sequences or other regulatory sequences such as enhancer sequences, e.g. from SV40, adenovirus, LTR of retrovirus, or of immunoglobulin genes, polyadenylation sequences, or selectable marker sequences. Suitable expression vectors can be obtained using conventional cloning techniques, as e.g. described in the standard manual by Sambrook et al. (1989) Molecular cloning: a
15 laboratory manual, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

The term "host cell" comprises a cell, which is stably transformed with a heterologous nucleic acid molecule, and hence contains the nucleic acid molecule or
20 at least parts thereof in its genome, and wherein the nucleic acid molecule carries a gene, which is expressed, i.e. transcribed and translated, by the cell, and, optionally, the gene product is secreted by the cell.

To establish recombinant cell lines various transformation techniques may be
25 employed. Preferably, the cells are transfected with the calcium phosphate method (described in Example 2). However, other conventional transfection methods can be used, such as DEAE-dextran mediated transfection techniques, lysozyme fusion, protoplast fusion or erythrocyte fusion, scraping, direct uptake, osmotic or sucrose shock, direct microinjection, indirect microinjection such as via erythrocyte-mediated
30 techniques, or by subjecting the host cells to electric currents.

Generally, by transfection or transformation is meant the transfer of genetic information, and especially the information encoded by a cDNA or genomic

5 erythropoietin clone, into a cell using isolated DNA, RNA, or a synthetic nucleotide polymer by recombinant DNA technology. The transfer of genetic information, particularly of a DNA sequence coding for human erythropoietin, into the cell can be confirmed by cotransfection of the cell with a selectable marker, preferably by using the tryptophan synthetase gene from *E. coli* as the selectable marker.

10

For the cultivation of the mammalian cells, common culturing methods can be applied, e.g. suspension culture using flasks or dishes usually used for tissue culture, methods of growing the cells in suspension by stirring the culture medium in spinner vessels, methods of growing the cells in hollow fibres into which culture medium is continuously circulated and methods of growing the cells in jar fermentors for cultivation of animal cells.

15

After the cultivation of the mammalian cells, the recombinant expression product may be recovered in substantially purified form from the culture media using conventional purification techniques, such as affinity chromatography, ion exchange chromatography, hydrophobic interaction chromatography, adhesion chromatography (hydroxyapatite), gel filtration, dye chromatography or reversed phase chromatography.

20

25 Finally, the biological activity of the recovered erythropoietin can be determined by several different methods. Kurtz and Eckardt reviewed the current assays in Nephron (1989);51 Suppl 1:11-14.

25

30 **Description of the Figures**

30

Fig. 1 shows a Western Blot from supernatant of eight selected BHK 21 pMPSVgEPO and eight selected CHO K1:CycE pMPSVgEPO clones.

5

Fig. 2 shows a silver stained SDS polyacrylamide gel of cell culture supernatant from BHK21 pMPSVgEPO clone 2. Lane 1 shows unconcentrated supernatant, whereas lane 2 shows a ten times concentrated supernatant.

10

Fig. 3 shows a sample of purified recombinant erythropoietin analysed by Coomassie stained SDS PAGE.

The invention will now be explained in more detail by way of example.

15

Example 1

Preparation of the erythropoietin expression vector pMPSVgEPO

The human erythropoietin gene was obtained from the American Type Culture
20 Collection as a lambda HE 1 phage lyophilisate (Lin *et al.*, supra, ATCC Number 40381). Sufficient quantities of lambda phage carrying a fragment containing the genomic DNA for human erythropoietin were prepared by suspending the phage lyophilisate in SM buffer (Sambrook *et al.*, supra) and plating the phage on LE 392 *E. coli* cells in LB agar containing 0.3% glucose, 0.075 mM CaCl₂, 0.004 mM FeCl₃,
25 2 mM MgSO₄ and 1 mg/ml maltose. The phage particles were harvested overnight with 10 ml SM per 15 cm petri dish. The phage DNA of 50 ml of this lysate was purified with the aid of the Qiagen Lambda kit according to manufacturer's instructions (Qiagen, Hilden, Germany). 50 % of the resulting DNA were taken up in
30 20 µl H₂O and digested with 30 units each of restriction endonucleases *Hind*III and *Bam*HI (New England Biolabs (NEB), Schwalbach, Germany). A 5.4 kb fragment was eluted from an 0.8 % agarose gel with the aid of the Gene Clean Kit of Bio 101 (Vista CA, USA). This 5.4 kb fragment contains the entire coding of the human erythropoietin gene, which contains four intervening sequences and five exons (cf.

- 14 -

5 also Lin *et al.*, supra). The vector pMPSVHE (Artelt *et al.*, supra), carrying the MPSV promoter, was digested with restriction endonuclease *Hind*III and *Bam*HI according to manufacturer's instructions (NEB), and the linearized vector DNA was gel purified using the Gene Clean Kit Bio 101. Approximately 0.5 µg of the vector DNA and 2 µg of the purified erythropoietin gene insert were ligated using T4 DNA
10 Ligase (NEB) and the product was transformed into RbCl₂ competent DH5alpha *E. coli* cells (Sambrook *et al.*, supra). After identification of a colony with correct insert by restriction analysis and large scale preparation of plasmid DNA by use of the Qiagen Midiprep Kit, an 575 bp fragment was deleted from the 5' end of the erythropoietin gene insert by digesting the vector with the restriction enzymes
15 *Hind*III and *Bst*EII (NEB) in the presence of buffer 2 (NEB); see also Lin *et al.*, supra, for a restriction map of the erythropoietin gene insert. The sticky ends were filled with T7 DNA polymerase (NEB) at 37 °C for 30 min. in the presence of all 4 nucleotides. The product of this fill-in reaction was ligated at 16 °C for 30 min. in the presence of T4 DNA Ligase (NEB) and subsequently transformed into RbCl₂
20 competent DH5alpha *E. coli* cells. After restriction analysis, an *E. coli* clone with the correct vector construct was identified and larger quantities of said vector DNA were prepared with the aid of the Qiagen Midiprep Kit according to manufacturer's instruction. The resulting vector, carrying the genomic erythropoietin gene under control of the MPSV promoter, was designated pMPSVgEPO.

25 Example 2

Stable transfection of BHK 21 and CHO K1:cycE cells with the pMPSVgEPO vector

30 The tryptophan synthetase gene (*trpB*) of *E. coli* was used for stable selection of the pMPSVgEPO vector. In this system, transfected cells are selected by their ability to

- 15 -

5 convert indole into the essential amino acid tryptophan by enzymatic activity of the gene product of the tryptophan synthetase gene (*trpB*).

Prior to CaPO_4 transfection, the expression vector was linearized with the restriction enzyme *AatII*, and the *trpB* selection plasmid pSV2*trpB* (described in Hartman and Mulligan, supra) was linearized with the restriction endonuclease *EcoRI*. A mixture
10 of 5.7 μg of pMPSVgEPO and 0.3 μg pSV2*trpB* was prepared in 30 μl H_2O . 30 μl of 1 M CaCl_2 solution were added and mixed. 60 μl of phosphate solution (50 mM HEPES, 280 mM NaCl, 1.5 mM Na_2HPO_4 , pH 7.05, sterile filtered, not autoclaved) were added and vortexed for 5 seconds. After incubation for 25 seconds at room
15 temperature, the precipitate was transferred to a polypropylene tube with 2 ml of Turbodoma medium with 2 % fetal calf serum (FCS).

The medium of 80% confluent BHK 21 and CHO K1:cycE cell cultures (Renner *et al.* Biotech. Bioeng. 47, 476-482, 1995) in six well plate were removed and the cells
20 were washed once with serum-free Turbodoma medium. After addition of the 2 ml medium with the precipitate, the cell culture was incubated for 5 hours at 37 °C and 5 % CO_2 . The precipitate was removed and Turbodoma medium containing 15 % glycerol (Sigma) and 2 % FCS were added. After 30 seconds the medium with the glycerol was removed and 5 ml of medium containing 10 % FCS were added, and the
25 plate was rocked a few times. The medium was replaced with 3 ml of fresh serum-free medium and after 18 hours the cells were transferred into a 15 cm cell culture petri dish filled with 50 ml selection medium containing 300 μM indole instead of tryptophan plus 5 % of dialysed fetal calf serum (Life Technologies). After incubation for ten days, primary clones were visible and picked after overlaying the
30 culture with 0.8 % agarose. A 1.6 % agarose solution was prepared in PBS without Mg and Ca, autoclaved and cooled to 42 °C. This solution was mixed in a 1:1 ratio with prewarmed medium (42 °C) and the plate was overlayed with 30 ml of this

- 16 -

5 solution. After gelling at room temperature, the colonies were picked with a pipette. Residual cells that stuck to the cell culture plastic were detached with trypsin.

Primary clones were grown in a 24 well plate and then in T25 flasks in serum-free Turbodoma medium. The productivity of eight selected BHK 21 and CHO K1:cycE
10 cell clones were assayed in Western Blot analysis. The productivity in all BHK 21 cell clones was at least ten fold higher than that of CHO K1:cycE cells as compared in Western Blot analysis (see figure 1). All BHK 21 clones produced recombinant erythropoietin in significant amounts.

15 The two best producers (clone 2 and 10) were tested in different cell culture systems in suspension and on microcarriers. Examples 3 and 4 give details.

Example 3

20 Production of recombinant human erythropoietin in suspension culture

BHK21 pMPSVgEPO, clone 2 was grown in Spinner flasks (Integra Bioscience) in suspension in serum-free and protein-free Turbodoma medium. 20 million cells grown in T-flasks were detached with Cell Dissociation Solution (Sigma) and
25 inoculated in 200 ml of Turbodoma medium supplemented with 0.5 g/l Pluronic F68 (Sigma) in a spinner flask. Culture conditions were: 37°C, 5% CO₂, rotation of 20 rpm. Starting with a density of 100,000 cells/ml, the cells grew within 4 days to a cell density of approximately 1 million cells/ml. After seven days the cell culture was harvested and the culture liquid was centrifuged for three minutes at 250 g. The
30 supernatant was analysed by SDS PAGE and a strong band was detected at a molecular weight of approximately 34 - 38 kD (figure 2). This band was confirmed in Western blot analysis to be crossreactive with an anti erythropoietin antibody

5 (Research Diagnostics, USA). As can be seen in figure 2, the product represents about 50 % of the total protein in the supernatant.

Example 4

10 Production of recombinant human erythropoietin in microcarrier culture

BHK21 pMPSVgEPO, clone 2 was grown attached on microcarriers in Spinner flasks (Integra Bioscience) in serum-free and protein-free Turbodoma HP-1 medium (F. Messli Cell Culture Technologies). 20 million cells grown in T-flasks were
15 detached with Cell Dissociation Solution (Sigma) and inoculated with 0.6 g of Cytodex 1 microcarriers (Pharmacia) in 25ml of Turbodoma HP-1 medium during 5 hours in the presence of 5% CO₂ and at 37°C. The microcarriers were prepared as described in the manufacturer's instructions. The culture was transferred into a spinner flask with 200 ml Turbodoma HP-1 medium supplemented with 0.5 g/l
20 Pluronic F68 (Sigma). Culture conditions were: 37°C, 5% CO₂, rotation of 20 rpm. Starting with a density of 100,000 cells/ml, the cells grew within 4 days to confluency. At day 4 the microcarriers were allowed to settle and 70% of the medium were replaced with fresh medium. At days 5 and 6 each, another 40 % of the medium were replaced with fresh medium and at day 7 the culture was harvested. The
25 supernatant contained recombinant human erythropoietin at a concentration of 10 mg/l as determined by ELISA (EPO ELISA, Boehringer Mannheim). This recombinant erythropoietin product was purified as described in example 5.

5 **Example 5**

Purification of recombinant human erythropoietin

10 This example relates to a purification of human recombinant EPO from cell culture supernatant fluid. This process comprising the following steps:

- A. Dye Chromatography on Blue Sepharose
- B. Hydrophobic Interaction Chromatography on Butyl-Toyopearl
- C. Chromatography on Hydroxylapatite
- D. Anion Exchange Chromatography on Resource Q

15 revealed in a polypeptide component at about 34,000 MW when analyzed by SDS-PAGE according Laemmli, U.K. and stained with Coomassie or Silver.

A. Dye Chromatography

20 The pH of the cell-free culture supernatant was adjusted to pH 5.0 with acetic acid and was filtered through a 0.45 µm filter at 4°C to 10°C. The filtrate, in this example 200ml, was applied onto a 5ml blue sepharose CL-6B (Pharmacia) column previously equilibrated with 20mM sodium acetate, 5mM CaCl₂ and 100mM NaCl at pH 5.0 with 4ml/min at 10°C. The gel was washed with 5CV of 20mM sodium acetate, 5mM CaCl₂ and 250mM NaCl at pH 5.0 and 5CV of 20mM Tris-HCl, 5mM
25 CaCl₂ at pH 6.5, respectively. The protein was eluted with 2CV of 100mM Tris-HCl, 5mM CaCl₂ and 1M NaCl at pH 9.0.

B. Hydrophobic Interaction Chromatography

30 The eluate from the blue sepharose column was brought to pH 6.9 with 1N HCl immediately after chromatography, and to 10% isopropanol before loading. A 5ml column with Butyl-Toyopearl (TosoHaas) was run at room temperature and equilibrated with 20mM Tris-HCl, 5mM CaCl₂, 750mM NaCl, 10% isopropanol at pH 6.9. After loading the protein sample the column was washed with 20mM Tris-

- 19 -

5 HCl, 5mM CaCl_2 , 750mM NaCl and 19% isopropanol at pH 6.9. The proteins, predominantly EPO, were eluted with 20mM Tris-HCl, 5mM CaCl_2 , 750mM NaCl and 27% isopropanol at pH 6.9. The fraction was diluted one third with 20mM Tris-HCl, 5mM CaCl_2 at pH 6.9.

10 C. Chromatography on Hydroxylapatite

A 5ml column with Hydroxylapatite Ultrogel was run at room temperature and equilibrated with 20mM Tris-HCl, 5mM CaCl_2 , 250mM NaCl, 9% isopropanol, pH 6.9. After loading the diluted eluate from the previous step the column was washed with 5CV of 10mM Tris-HCl, 5mM CaCl_2 , pH 6.8. The protein was eluted with
15 20mM Tris-HCl, 5mM CaCl_2 , 750mM NaCl and 27% isopropanol, pH 6.9. The fraction was diluted one third with 10mM Tris-HCl, 10mM sodium phosphate and 5mM CaCl_2 , pH 6.9.

D. Anion Exchange Chromatography

20 For a final purification step a 1ml Resource Q column (Pharmacia) was applied at 15°C. The column was equilibrated with 10mM sodium phosphate, pH 7.0. The eluate from the hydroxyapatite column was loaded, followed by a washing step with equilibration buffer for 2CV. Finally, the bound erythropoietin was released by elution with 10mM sodium phosphate, 250mM NaCl at pH 7.0 where traces of DNA
25 remain on the column. The protein fraction was concentrated 10 times by means of an ultrafree-15 5k ultrafilter (Millipore) and diluted with 2 volumes of 10mM sodium phosphate, pH 7.0.

A sample of the resulting erythropoietin product has been analysed on Coomassie
30 stained SDS PAGE. 70 μg of purified recombinant human erythropoietin were loaded, and, as shown in figure 3 the product is essentially free of any host cell derived proteins.

- 5 While the present invention has been described in conjunction with preferred embodiments, one of ordinary skill after reading the foregoing specification will be able to effect various changes, substitutions or equivalents, and other alterations to the methods set forth herein.

5

C L A I M S

1. A process for production of human erythropoietin in a mammalian host cell, comprising the step of culturing the host cell under suitable nutrient conditions, wherein the host cell is transformed or transfected with an expression vector comprising a DNA sequence that codes for human erythropoietin under control of the myeloproliferative sarcoma virus promoter, and wherein the nutrient conditions comprise serum-free and protein-free culture medium.
2. The process according to claim 1, wherein the DNA sequence originates from a genomic clone.
3. The process according to claim 1 or 2, wherein the host cell is a kidney cell.
4. The process according to claim 3, wherein the cell is a baby hamster kidney cell, preferably a BHK 21 cell.
5. The process according to any one of the preceding claims, wherein the serum-free and protein-free culture medium is Turbodoma medium.
6. The process according to any one of the preceding claims, wherein the host cell is selected by its ability to produce tryptophan.
7. The process according to claim 6, wherein the host cell is able to produce tryptophan due to expression of the tryptophan synthetase (trpB) gene of *Escherichia coli*.


5 8. The process according to any one of the preceding claims, further comprising the step of recovering the erythropoietin from the cell culture medium after cultivation of the host cell.

 9. A mammalian host cell transformed or transfected with an expression
10 vector comprising a DNA sequence that codes for human erythropoietin under control of the myeloproliferative sarcoma virus promoter and cultured in serum-free and protein-free culture medium.

 10. The mammalian host cell according to claim 9, which is able to
15 produce tryptophan due to expression of the tryptophan synthetase (trpB) gene of *Escherichia coli*.


 11. The mammalian host cell according to claim 9 or claim 10, which is a
20 kidney cell, preferably a baby hamster kidney cell, and most preferably a BHK 21 cell.

Fig. 1




2 / 3

Fig. 2



3 / 3

Fig. 3



INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/EP 99/06465

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/85 C07K14/505 C12N5/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>LIN J H ET AL: "Expression efficiency of the human thrombomodulin-encoding gene in various vector and host systems" GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 147, no. 2, page 287-292 XP002091310 ISSN: 0378-1119 abstract; table 2</p> <p style="text-align: center;">— — — — — -/-</p>	1-11

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

7 February 2000

Date of mailing of the international search report

24/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Hardon, E

INTERNATIONAL SEARCH REPORT

Internatic Application No

PCT/EP 99/06465

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ARTELT P ET AL: "VECTORS FOR EFFICIENT EXPRESSION IN MAMMALIAN FIBROBLASTOID, MYELOID AND LYMPHOID CELLS VIA TRANSFECTION OR INFECTION" GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 68, no. 2 + INDEX, page 213-219 XP000000152 ISSN: 0378-1119 the whole document	1-11
Y	ONODERA ET AL: "Development of improved adenosine deaminase retroviral vectors" JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 72, no. 3, page 1769-1774 XP002091309 ISSN: 0022-538X abstract; tables 1,2	1-11
Y	DATABASE MEDLINE 'Online! /an 96115464, 1995 RAUSCHENBACH R.: "Stable expression... " XP002091756 abstract	1-11
Y	VANDENDRIESSCHE M C T ET AL: "Development and analysis of retroviral vectors expressing human Factor-VIII and Factor-IX" BIOTECHABS,XX,XX, no. 236 Suppl. 18A, XP002091311 abstract	1-11
Y	ZANG M ET AL: "PRODUCTION OF RECOMBINANT PROTEINS IN CHINESE HAMSTER OVARY CELLS USING A PROTEIN-FREE CELL CULTURE MEDIUM" BIO/TECHNOLOGY,US,NATURE PUBLISHING CO. NEW YORK, vol. 13, page 389-392 XP002032677 ISSN: 0733-222X the whole document	1-11
Y	EP 0 653 487 A (MESSI FERRUCCIO DR) 17 May 1995 (1995-05-17) the whole document	5-11
Y	STOLL, T. S. ET AL: "Systematic improvement of a chemically-defined protein-free medium for hybridoma growth and monoclonal antibody production" J. BIOTECHNOL. (1996), 45(2), 111-23 , 1996, XP004036827 the whole document	5-11

	--- -/---	

INTERNATIONAL SEARCH REPORT

Internati Application No

PCT/EP 99/06465

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 148 605 A (KIRIN AMGEN INC) 17 July 1985 (1985-07-17) cited in the application example 10	1-11
A	WO 98 26084 A (RENNER WOLFGANG ANDREAS; BAILEY JAMES EDWIN (CH)) 18 June 1998 (1998-06-18) claims 13,15	1-11
A	EP 0 531 911 A (DOERR HANS WILHELM PROF DR MED) 17 March 1993 (1993-03-17) cited in the application table 2	1-11
A	HARTMAN S C ET AL: "Two dominant-acting selectable markers for gene transfer studies in mammalian cells." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1988 NOV) 85 (21) 8047-51. , XP000872814	7-11
A	EGLITIS, M.A.: "Positive selectable markers for use with mammalian cells in culture." HUMAN GENE THERAPY, vol. 2, 1991, pages 195-201, XP000872273 page 198, column 2, line 5-30	7-11

INTERNATIONAL SEARCH REPORT
Information on patent family members

Internat Application No
PCT/EP 99/06465

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0653487	A	17-05-1995	NONE	
EP 0148605	A	17-07-1985	US 4703008 A	27-10-1987
			AT 54940 T	15-08-1990
			AU 1007495 A	06-04-1995
			AU 657555 B	16-03-1995
			AU 2042192 A	08-10-1992
			AU 3612597 A	18-12-1997
			AU 600650 B	23-08-1990
			AU 3746785 A	26-06-1985
			AU 5272293 A	24-03-1994
			AU 5750490 A	04-10-1990
			AU 6981798 A	20-08-1998
			CA 1339047 A	27-05-1997
			CY 1643 A	14-05-1993
			DK 365185 A	11-10-1985
			ES 538519 A	01-05-1988
			HK 20093 A	19-03-1993
			IL 73785 A	15-11-1992
			IL 96581 A	13-05-1993
			IL 96582 A	04-04-1993
			IL 100935 A	04-04-1993
			JP 2708099 B	04-02-1998
			JP 8269096 A	15-10-1996
			JP 6093000 A	05-04-1994
			JP 7076239 B	16-08-1995
			JP 2957974 B	06-10-1999
			JP 10095799 A	14-04-1998
			JP 10072366 A	17-03-1998
			JP 1055190 A	02-03-1989
			JP 2107224 C	06-11-1996
			JP 6055136 B	27-07-1994
			JP 1975769 C	27-09-1995
			JP 3198792 A	29-08-1991
			JP 4035159 B	10-06-1992
			JP 2655750 B	24-09-1997
			JP 3259098 A	19-11-1991
			JP 11253188 A	21-09-1999
			JP 2017156 B	19-04-1990
			JP 61501627 T	07-08-1986
			MX 9203598 A	01-09-1992
			NZ 210501 A	27-08-1991
			NZ 227326 A	27-08-1991
			NZ 227327 A	27-08-1991
			SG 92891 G	14-02-1992
			WO 8502610 A	20-06-1985
			US 5955422 A	21-09-1999
			US 5441868 A	15-08-1995
			US 5756349 A	26-05-1998
			US 5618698 A	08-04-1997
			US 5621080 A	15-04-1997
			US 5547933 A	20-08-1996
WO 9826084	A	18-06-1998	AU 7637796 A	03-07-1998
EP 0531911	A	17-03-1993	EP 0531562 A	17-03-1993
			AT 161040 T	15-12-1997
			DE 59209058 D	22-01-1998

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/EP 99/06465

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0531911 A		ES 2111590 T	16-03-1998
		GR 3026160 T	29-05-1998
		JP 5252943 A	05-10-1993
		US 5393668 A	28-02-1995